iRadimed
IRMD
168 hedge funds and large institutions have $365M invested in iRadimed in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 70 increasing their positions, 51 reducing their positions, and 17 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 51
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
1% more funds holding
Funds holding: 167 → 168 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.29% less ownership
Funds ownership: 55.01% → 54.73% (-0.29%)
5% less capital invested
Capital invested by funds: $383M → $365M (-$18.1M)
97% less call options, than puts
Call options by funds: $5K | Put options by funds: $167K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
Roubaix Capital
Denver,
Colorado
|
+$2.7M |
| 2 |
Millennium Management
New York
|
+$1.47M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.27M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$991K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$915K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$2.51M |
| 2 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
-$1.91M |
| 3 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$1.62M |
| 4 |
AAIS
ABN AMRO Investment Solutions
Paris Cedex 008,
|
-$1.59M |
| 5 |
Squarepoint
New York
|
-$867K |
IRMD Hedge Fund Activity: Q1 2025 in Review
168 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q1 2025, worth a combined $365M — down 4.7% from $383M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IRMD positions and 17 closed out — a net gain of 1 holder — while 70 added to existing stakes and 51 trimmed.
The largest buyer was Roubaix Capital, opening a new position worth an estimated $2.7M. The largest seller was Ranger Investment Management, cutting an estimated $2.51M.
- 168 institutional investors held iRadimed (IRMD) as of Q1 2025, up from 167 in Q4 2024.
- Funds reported $365M of iRadimed stock for Q1 2025, down 4.7% quarter-over-quarter.
- 18 funds opened new iRadimed positions in Q1 2025 and 17 closed out, a net change of +1 holder.
- The largest iRadimed buyer in Q1 2025 was Roubaix Capital, an estimated $2.7M added.
- The largest iRadimed seller in Q1 2025 was Ranger Investment Management, an estimated $2.51M sold.
Based on aggregated 13F filings for Q1 2025.